Inclusion Criteria:  Participants (>=12 years) with investigator confirmed diagnosis of HAE. Have received at least one dose of lanadelumab according to approved indications. Signed the mandatory consent that has been agreed with national regulatory authorities (ANMAT) as applicable.  Exclusion Criteria:  - Hypersensitivity to the active substance or to any of the excipients.